Bright Minds Biosciences Inc
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials… Read more
Bright Minds Biosciences Inc (DRUG) - Net Assets
Latest net assets as of December 2025: $89.28 Million USD
Based on the latest financial reports, Bright Minds Biosciences Inc (DRUG) has net assets worth $89.28 Million USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($90.88 Million) and total liabilities ($1.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $89.28 Million |
| % of Total Assets | 98.24% |
| Annual Growth Rate | 193.84% |
| 5-Year Change | 322.87% |
| 10-Year Change | N/A |
| Growth Volatility | 965.04 |
Bright Minds Biosciences Inc - Net Assets Trend (2019–2025)
This chart illustrates how Bright Minds Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bright Minds Biosciences Inc (2019–2025)
The table below shows the annual net assets of Bright Minds Biosciences Inc from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-09-30 | $82.04 Million | +1381.93% |
| 2024-09-30 | $5.54 Million | -16.09% |
| 2023-09-30 | $6.60 Million | -37.41% |
| 2022-09-30 | $10.54 Million | -45.66% |
| 2021-09-30 | $19.40 Million | +2560.36% |
| 2020-09-30 | $729.29K | +473.06% |
| 2019-09-30 | $127.26K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bright Minds Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4649960000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $123.25 Million | 150.22% |
| Other Comprehensive Income | $5.37 Million | 6.55% |
| Total Equity | $82.04 Million | 100.00% |
Bright Minds Biosciences Inc Competitors by Market Cap
The table below lists competitors of Bright Minds Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Enaex S.A
SN:ENAEX
|
$477.00 Million |
|
Jinhui Liquor Co Ltd
SHG:603919
|
$477.07 Million |
|
Nuvoton Technology Corp
TW:4919
|
$477.41 Million |
|
Happinet Corporation
PINK:HAPYF
|
$477.57 Million |
|
Rogers Sugar Inc
PINK:RSGUF
|
$476.94 Million |
|
Shen Ma Industry Co Ltd
SHG:600810
|
$476.84 Million |
|
Seegene Inc
KQ:096530
|
$476.58 Million |
|
Guangdong Haomei New Material Co Lt
SHE:002988
|
$476.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bright Minds Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 5,536,343 to 82,044,923, a change of 76,508,580 (1381.9%).
- Net loss of 12,229,348 reduced equity.
- New share issuances of 82,097,564 increased equity.
- Other comprehensive income increased equity by 1,367,034.
- Other factors increased equity by 5,273,330.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.23 Million | -14.91% |
| Share Issuances | $82.10 Million | +100.06% |
| Other Comprehensive Income | $1.37 Million | +1.67% |
| Other Changes | $5.27 Million | +6.43% |
| Total Change | $- | 1381.93% |
Book Value vs Market Value Analysis
This analysis compares Bright Minds Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.05x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 725.88x to 6.05x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | $0.10 | $72.13 | x |
| 2020-09-30 | $0.57 | $72.13 | x |
| 2021-09-30 | $10.81 | $72.13 | x |
| 2022-09-30 | $4.27 | $72.13 | x |
| 2023-09-30 | $1.77 | $72.13 | x |
| 2024-09-30 | $1.28 | $72.13 | x |
| 2025-09-30 | $11.93 | $72.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bright Minds Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -14.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-14.91%) is above the historical average (-87.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -185.56% | 0.00% | 0.00x | 1.29x | $-248.88K |
| 2020 | -66.63% | 0.00% | 0.00x | 1.21x | $-558.87K |
| 2021 | -43.89% | 0.00% | 0.00x | 1.03x | $-10.46 Million |
| 2022 | -141.95% | 0.00% | 0.00x | 1.15x | $-16.02 Million |
| 2023 | -111.73% | 0.00% | 0.00x | 1.04x | $-8.03 Million |
| 2024 | -50.61% | 0.00% | 0.00x | 1.10x | $-3.36 Million |
| 2025 | -14.91% | 0.00% | 0.00x | 1.03x | $-20.43 Million |
Industry Comparison
This section compares Bright Minds Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bright Minds Biosciences Inc (DRUG) | $89.28 Million | -185.56% | 0.02x | $476.95 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |